Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: Effects on lipoproteins and atherosclerosis

Journal of Lipid Research

Volumn 40, Issue 12, 1999, Pages 2185-2194

  Kako, Yuko ^a   Huang, Li Shin ^a   Yang, James ^a   Katopodis, Tommy ^a   Ramakrishnan, Rajasekhar ^a   Goldberg, Ira J ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

Apolipoprotein; Cholesterol; Coronary; Heart; Triglyceride

Indexed keywords

APOLIPOPROTEIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE PERMEABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ANIMAL FEED; ANIMALS; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, DIETARY; CHROMATOGRAPHY, GEL; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; SEX FACTORS; TRIGLYCERIDES;

EID: 0033391070     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. King, G. L., A. D. Goodman, S. Buzney, A. Moses, and C. R. Kahn. 1985. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 75: 1028-1036.
2. Cruzado, M., N. Risler, C. Castro, A. Ortiz, and M. E. Ruttler. 1998. Proliferative effect of insulin on cultured smooth muscle cells from rat mesenteric resistance vessels. Am. J. Hypertens. 11: 54-58.
3. Schmidt, A. M., O. Hori, J. X. Chen, J. F. Li, J. Crandall, J. Zhang, R. Cao, S. D. Yan, J. Brett, and D. Stern. 1995. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96: 1395-1403.
4. Brownlee, M., A. Cerami, and H. Vlassara. 1988. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318: 1315-1320.
5. Caixas, A., J. Ordonez-Llanos, A. de Leiva, A. Payes, R. Homs, and A. Perez. 1997. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 46: 1207-1213.
6. Ginsberg, H. N. 1996. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 45 Suppl 3: S27-30.
7. Yost, T. J., K. K. Froyd, D. R. Jensen, and R. H. Eckel. 1995. Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. Metabolism. 44: 786-790.
8. Bagdade, J. D., D. E. Kelley, R. R. Henry, R. H. Eckel, and M. C. Ritter. 1997. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes. 46: 414-420.
9. Breslow, J. L. 1996. Mouse models of atherosclerosis. Science. 272: 685-688.
10. Callow, M. J., J. Verstuyft, R. Tangirala, W. Palinski, and E. M. Rubin. 1995. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J. Clin. Invest. 96: 1639-1646.
11. Purcell-Huynh, D. A., R. V. Farese, Jr., D. F. Jonhson, L. M. Flynn, V. Pierotti, D. L. Newland, M. F. Linton, D. A. Sanan, and S. G. Young. 1995. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95: 2246-2257.
12. Voyiaziakis, E., I. J. Goldberg, A. S. Plump, E. M. Rubin, J. L. Breslow, and L. S. Huang. 1998. ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. J. Lipid Res. 39: 313-321.
13. Callow, M. J., L. J. Stoltzfus, R. M. Lawn, and E. M. Rubin. 1994. Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice. Proc. Natl. Acad. Sci. USA. 91: 2130-2134.
14. Levak-Frank, S., H. Radner, A. Walsh, R. Stollberger, G. Knipping, G. Hoefler, W. Sattler, P. H. Weinstock, J. L. Breslow, and R. Zechner. 1995. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J. Clin. Invest. 96: 976-986.
15. Yin, B., J. D. Loike, Y. Kako, P. H. Weinstock, J. L. Breslow, S. C. Silverstein, and I. J. Goldberg. 1997. Lipoprotein lipase regulates Fc receptor-mediated phagocytosis by macrophages maintained in glucose-deficient medium. J. Clin. Invest. 100: 649-657.
16. Kunjathoor, V., D. Wilson, and R. LeBoeuf. 1996. Increased atherosclerosis in streptozotocin-induced diabetic mice. J. Clin. Invest. 97: 1767-1773.
17. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
18. Nilsson-Ehle, P., and M. C. Schotz. 1976. A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J. Lipid Res. 17: 536-541.
19. Goldberg, I., J. Paterniti, Jr., D. France, G. Martinelli, and J. Cornicelli. 1986. Production and use of an inhibitory monoclonal antibody to human lipoprotein lipase. Biochim. Biophys. Acta. 878: 168-176.
20. Merkel, M., P. Weinstock, T. Chajek-Shaul, H. Radner, B. Yin, J. Breslow, and I. Goldberg. 1998. Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia. J. Clin. Invest. 102: 893-901.
21. Levak-Frank, S., P. H. Weinstock, T. Hayek, R. Verdery, W. Hofmann, R. Ramakrishnan, W. Sattler, J. L. Breslow, and R. Zechner. 1997. Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma. J. Biol. Chem. 272: 17182-17190.
22. Shimada, M., S. Ishibashi, T. Gotoda, M. Kawamura, K. Yamamoto, T. Inaba, K. Harada, J. Ohsuga, S. Perrey, Y. Yazaki, et al. 1995. Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1688-1694.
23. Tavangar, K., Y. Murata, M. Pedersen, J. Goers, A. Hoffman, and F. Kraemer. 1992. Regulation of lipoprotein lipase in the diabetic rat. J. Clin. Invest. 90: 1672-1678.
24. Ginsberg, H. N. 1987. Very low density lipoprotein metabolism in diabetes mellitus. Diabetes Metab. Rev. 3: 571-589.
25. Bar-on, H., Y. Chen, and G. Reaven. 1981. Evidence for a new cause of defective plasma removal of very low density lipoproteins in insulin-deficient rats. Diabetes. 30: 496-499.
26. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
27. Jong, M. C., M. J. Gijbels, V. E. Dahlmans, P. J. Gorp, S. J. Koopman, M. Ponec, M. H. Hofker, and L. M. Havekes. 1998. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein Cl. J. Clin. Invest. 101: 145-152.
28. Huang, Y., X. Q. Liu, S. C. Rall, Jr., J. M. Taylor, A. von Eckardstein, G. Assmann, and R. W. Mahley. 1998. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273: 26388-26393.
29. Chen, M., J. L. Breslow, W. Li, and T. Leff. 1994. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. 35: 1918-1924.
30. Huff, M. W., D. B. Miller, B. M. Wolfe, P. W. Connelly, and C. G. Sawyez. 1997. Uptake of hypertriglyceridemic very low density lipoproteins and their remnants by HepG2 cells: the role of lipoprotein lipase, hepatic triglyceride lipase, and cell surface proteoglycans. J. Lipid Res. 38: 1318-1333.
31. Semenkovich, C. F., T. Coleman, and A. Daugherty. 1998. Effects of heterozygous lipoprotein lipase deficiency on diet-induced atherosclerosis in mice. J. Lipid Res. 39: 1141-1151.
32. Taskinen, M. R., T. Kuusi, E. Helve, E. A. Nikkila, and H. Yki-Jarvinen. 1988. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis. 8: 168-177.
33. Ma, Y., M. S. Liu, D. Ginzinger, J. Frohlich, J. D. Brunzell, and M. R. Hayden. 1993. Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172→Cys mutation in the lipoprotein lipase gene. J. Clin. Invest. 91: 1953-1958.
34. Dichek, H. L., W. Brecht, J. Fan, Z. S. Ji, S. P. McCormick, H. Akeefe, L. Conzo, D. A. Sanan, K. H. Weisgraber, S. G. Young, J. M. Taylor, and R. W. Mahley. 1998. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J. Biol. Chem. 273: 1896-1903.
35. Lambert, G., A. Remaley, M. Chase, K. Peterson, A. Bensadoun, H. Brewer, Jr., and S. Santamarina-Fojo. 1998. Role of hepatic lipase in the Cla-1 mediated selective uptake of HDL cholesterol esters (Abstract). Circulation. 98 (Suppl. I): 1-202.
36. Rinninger, F., T. Kaiser, W. A. Mann, N. Meyer, H. Greten, and U. Beisiegel. 1998. Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture. J. Lipid Res. 39: 1335-1348.
37. Reaven, P., S. Merat, F. Casanada, M. Sutphin, and W. Palinski. 1997. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 17: 2250-2256.
38. Park, L., K. G. Raman, K. J. Lee, Y. Lu, L. J. Ferran, Jr., W. S. Chow, D. Stern, and A. M. Schmidt. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4: 1025-1031.
39. Minnich, A., and D. B. Zilversmit. 1989. Impaired triacylglycerol catabolism in hypertriglyceridemia of the diabetic, cholesterol-fed rabbit: a possible mechanism for protection from atherosclerosis. Biochim. Biophys. Acta. 1002: 324-332.
40. Nordestgaard, B. G., S. Stender, and K. Kjeldsen. 1988. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 8: 421-428.
41. Duff, G., and G. MacMillan. 1949. The effect of alloxan diabetes on experimental atherosclerosis in the rabbits. J. Exp. Med. 89: 611-612.
42. Gerrity, R., J. Nadler, and R. Natarajan. 1997. Oxidant stress in a new swine model of diabetes-induced accelerated atherosclerosis (Abstract). Circulation. 96 (Suppl. I): I-175.
43. Hansson, L., A. Zanchetti, S. G. Carruthers, B. Dahlof, D. Elmfeldt, S. Julius, J. Menard, K. H. Rahn, H. Wedel, and S. Westerling. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 351: 1755-1762.
44. Pyorala, K., T. R. Pedersen, J. Kjekshus, O. Faergeman, A. G. Olsson, and G. Thorgeirsson. 1997. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20: 614-620.